The approval is based on data from the Phase III ALEX study, which showed that the drug significantly cut the risk of disease worsening or death by 53 percent compared to crizotinib. Median PFS was […]
The group says money saved from calling time on routine prescriptions for minor, short-term conditions, could be streamed into expanding access to other treatments for major conditions such as cancer and mental health problems. Potentially […]
Luxturna is said to be the first directly administered adeno-associated virus (AAV) vector gene therapy approved in the country to target a condition caused by mutations in a specific gene. The mutation associated retinal dystrophy […]
Spark Therapeutics has gained US Food and Drug Administration (FDA) approval for its one-time gene therapy product, Luxturna (voretigene neparvovec-rzyl), to treat children and adults with biallelic RPE65 mutation-associated retinal dystrophy. Luxturna is said to […]
The decision allows physicians to prescribe for HER2-positive early breast cancer (EBC) at high risk of recurrence. In the Phase III APHINITY study, the Perjeta (pertuzumab), Herceptin and chemotherapy regimen significantly cut the risk of […]